

### Wednesday, 15 November 2023

**15:00 – 18:00 Scientific Business Meeting** (only open to Lymphoma Working Party active members)

### Thursday, 16 November 2023

<b>09:00 – 10:05</b>	<b>Session 1</b> <i>Chairs: Iwona Hus (PL) &amp; Bertram Glass (DE)</i>	
09:00 – 09:05	Welcome and introduction	
09:05 – 09:35	Principles of SCT in lymphoma	Sebastian Giebel (PL)
09:35 – 10:05	Principles of CAR-T in lymphoma	Peter Dreger (DE)
<b>10:05 – 11:35</b>	<b>Session 2: Mantle cell lymphoma</b> <i>Chair: Norbert Schmitz (DE)</i>	
10:05 – 10:30	Changing landscape of MCL first-line treatment: ASCT and targeted therapie	Sascha Dietrich
10:30 – 10:55	Sequencing of therapies in MCL in the era of novel therapies – where is the pl alloSCT?	
10:55 – 11:15	Discussion and Q&A	Igor Auer
<b>11:15 – 11:45</b>	<b>Coffee break</b>	
<b>11:45 – 13:15</b>	<b>Session 3: Hodgkin Lymphoma</b> <i>Chair: Ali Bazarbachi (LB)</i>	
11:45 – 12:10	First-line treatment of HL	Paul J. Bröckelmann (DE)
12:10 – 12:35	Auto / allo SCT in refractory/relapsed HL	Anna Sureda (ES)
12:35 – 12:45	Case study: Neurological complication after autologous stem cell transplant in a patient with previous immune check point inhibitor treatment	Karla Oliveros (AR)
12:45 – 12:55	Case study: A case of nivolumab in relapsed gray zone lymphoma following allogenic HSCT: from ICANS to Complete Remission	Igor Age Kos (DE)
12:55 – 13:15	Discussion and Q&A	
<b>13:15 – 14:20</b>	<b>Lunch break</b>	
<b>14:20 – 16:40</b>	<b>Session 4: Aggressive B-cell lymphoma</b> <i>Chair: Peter Dreger (DE)</i>	
14:20 – 14:45	First-line treatment of aggressive B-cell lymphoma > state-of-the-art	Wojciech Jurczak (PL)
14:45 – 15:10	Debate: The role of ASCT in the second line of aggressive B-cell lymphoma therapy Yes -> pro ASCT No -> pro CART	Marek Trneny (CZ) Bertram Glass (DE) Bertram Glass (DE)
15:10 – 15:35	Third and subsequent lines strategies of aggressive B-cell lymphoma treatment	
15:35 – 16:00	How to use SCT and CAR-T in the treatment of CNS lymphoma	Anna Ossami Saidy (DE)
16:00 – 16:10	Case study: A 28-Year-Old Man with R/R Diffuse Large B-Cell Lymphoma (DLBCL)	Hulya Yilmaz (TR)
16:10 – 16:20	Case study: Successful bispecific antibody therapy followed by allogeneic stem cell transplantation in a patient with refractory THRLBCL	Joseph Kauer(DE)
16:20 – 16:40	Discussion and Q&A	

### Friday, 17 November 2023

<b>09:00 – 10:20</b>	<b>Session 5: Indolent lymphoma</b> <i>Chair: Jan Walewski (PL)</i>	
09:00 – 09:25	Clinical dilemma: how to choose between many new treatment options for RR FL patients? Which patients will benefit from SCT?	Silvia Montoto (UK)
09:25 – 09:50	New target and cellular therapies (SCT and CAR-T) for patients with MZL	Emanuele Zucca (CH)
09:50 – 10:10	Discussion and Q&A	
<b>10:10 – 10:40</b>	<b>Coffee break</b>	
<b>10:40 – 12:30</b>	<b>Session 6: T-cell lymphoma</b> <i>Chair: Iwona Hus (PL)</i>	
10:40 – 11:05	Standard and emerging therapies for anaplastic large cell lymphoma. The current role of SCT	Norbert Schmitz (DE)
11:05 – 11:30	Treatment of advanced cutaneous T-cell lymphoma – What's new?	To be announced
11:30 – 11:40	Case study	To be announced
11:40 – 11:50	Case study: Primary refractory angioimmunoblastic T-cell lymphoma successfully treated with haploidentical bone marrow transplant	Fernanda Azevedo
11:50 – 12:10	Discussion and Q&A	
<b>12:10 – 12:25</b>	<b>Closing remarks &amp; farewell</b>	

\* All presentations have 5 minutes included for Q&A after each one  
\*\* Case studies are 10 minutes including 3 minutes for Q&A after each one